U.S. markets open in 6 hours 3 minutes
  • S&P Futures

    4,462.25
    +16.50 (+0.37%)
     
  • Dow Futures

    34,843.00
    +169.00 (+0.49%)
     
  • Nasdaq Futures

    15,362.25
    +43.50 (+0.28%)
     
  • Russell 2000 Futures

    2,256.20
    +12.20 (+0.54%)
     
  • Crude Oil

    74.87
    +0.89 (+1.20%)
     
  • Gold

    1,759.90
    +8.20 (+0.47%)
     
  • Silver

    22.68
    +0.26 (+1.14%)
     
  • EUR/USD

    1.1716
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.4600
    0.0000 (0.00%)
     
  • Vix

    17.75
    -0.88 (-4.72%)
     
  • GBP/USD

    1.3687
    +0.0006 (+0.04%)
     
  • USD/JPY

    110.6240
    -0.0610 (-0.06%)
     
  • BTC-USD

    43,775.74
    +1,880.29 (+4.49%)
     
  • CMC Crypto 200

    1,090.93
    -12.13 (-1.10%)
     
  • FTSE 100

    7,108.53
    +57.05 (+0.81%)
     
  • Nikkei 225

    30,240.06
    -8.75 (-0.03%)
     

ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Geneva, Switzerland and Boston, MA – May 31, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that shareholders approved all Board proposals at its 2021 Annual General Meeting held on May 28, 2021.

The approved items are as follows:

  1. Shareholders approved the Annual Report, the Statutory Financial Statements and the Consolidated Financial Statements for Fiscal Year 2020

  2. Shareholders granted discharge to the Members of the Board of Directors and to the Executive Committee for year 2020

  3. Shareholders approved the proposed appropriation of the Financial Results for year 2020

  4. Shareholders approved the proposed elections to the Board of Directors and election of the Chairman of the Board of Directors

  5. Shareholders approved the proposed elections to the Compensation Committee

  6. Shareholders approved the re-election of PricewaterhouseCoopers SA as ObsEva SA’s Auditors and Independent Registered Public Accounting Firm

  7. Shareholders approved the re-election of Perréard de Boccard SA as Independent Representative

  8. Shareholders approved the proposed compensation of the Board of Directors and the Executive Committee

  9. Shareholders approved the proposed increase of ObsEva SA’s Authorized Share Capital

  10. Shareholders approved the proposed increase of ObsEva SA’s Conditional Share Capital for Financing Purposes

  11. Shareholders approved the proposed increase of ObsEva SA’s Conditional Share Capital for Equity Plans

  12. Shareholders approved the proposed change to ObsEva SA’s Equity Incentive Plan

For a detailed agenda, including items submitted to shareholders’ vote and related proposals of the Board of Directors, please refer to the full invitation, which may be found in the Investors / General Meetings section of the company’s website www.ObsEva.com

To access the general meetings section of the Company’s website, please click here.

To access the AGM 2021 section of the general meetings section directly, please click here.

To access the full invitation to the AGM 2021 directly, please click here.

About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

For further information, please contact:

CEO Office Contact:

Shauna Dillon

Shauna.dillon@obseva.ch

+41 22 552 1550

Investor Contact:

Joyce Allaire

jallaire@lifesciadvisors.com

+1 (617)-435-6602

#

Attachment